These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 10674711)

  • 1. Pharmacokinetics of selective serotonin reuptake inhibitors.
    Hiemke C; Härtter S
    Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
    Baumann P
    Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
    Baumann P; Rochat B
    Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
    Hirano K; Kimura R; Sugimoto Y; Yamada J; Uchida S; Kato Y; Hashimoto H; Yamada S
    Br J Pharmacol; 2005 Mar; 144(5):695-702. PubMed ID: 15678084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
    van Harten J
    Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The transfer of selective serotonin reuptake inhibitors to human milk].
    Nordeng H; Bergsholm YK; Bøhler E; Spigset O
    Tidsskr Nor Laegeforen; 2001 Jan; 121(2):199-203. PubMed ID: 11475200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE; Ahern D; Scatina J; Kao J
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
    Luong TT; Powers CN; Reinhardt BJ; Weina PJ
    Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
    Rasmussen BB; Brøsen K
    Ther Drug Monit; 2000 Apr; 22(2):143-54. PubMed ID: 10774624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in interactions of SSRIs.
    Brøsen K
    Int Clin Psychopharmacol; 1998 Sep; 13 Suppl 5():S45-7. PubMed ID: 9817620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients.
    Eap CB; Baumann P
    J Chromatogr B Biomed Appl; 1996 Nov; 686(1):51-63. PubMed ID: 8953192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
    Mandrioli R; Mercolini L; Saracino MA; Raggi MA
    Curr Med Chem; 2012; 19(12):1846-63. PubMed ID: 22414078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
    Hemeryck A; Belpaire FM
    Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.
    Hermann M; Waade RB; Molden E
    Ther Drug Monit; 2015 Aug; 37(4):546-9. PubMed ID: 25565671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.